Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FKJXB
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,257
Award facts
- Contract value 100% obligated
- $10,256.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,256.76 to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract utilizes firm fixed pricing with a completion date of April 25, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will be conducted at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications and medical supplies to military healthcare systems worldwide.
Dupixent (dupilumab) is a prescription biologic medication primarily used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis, representing a specialized pharmaceutical product within the Defense Health Agency's medical supply requirements. AmerisourceBergen's role as a primary pharmaceutical distributor for federal medical procurement reflects its established capability to fulfill complex pharmaceutical supply chains supporting military and veteran healthcare operations. The competitive award of this delivery order, consistent with the company's portfolio of federal contracts across multiple therapeutic domains, demonstrates its continued qualification to provide critical pharmaceutical products to support military readiness and personnel healthcare needs.
Quick answers
Who was awarded contract SPE2DB25FKJXB?
SPE2DB25FKJXB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on April 24, 2025.
How much is contract SPE2DB25FKJXB worth?
The government has obligated $10,257 on SPE2DB25FKJXB.
Is contract SPE2DB25FKJXB an order under another contract?
Yes. SPE2DB25FKJXB is a delivery order under SPE2DB24D2101, an indefinite delivery contract.
Was contract SPE2DB25FKJXB competed?
The extent of competition for SPE2DB25FKJXB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award